QYResearch is a leading market research publisher which pursuits high product quality with the belief that quality is the soul of business and consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience.

Los Angeles, CA -- (SBWire) -- 12/20/2018 --This study researches the market size of Hyperphosphatemia Drugs in United States, European Union and China, presents the Hyperphosphatemia Drugs sales, revenue, market share and growth rate by companies, type and application, history breakdown data from 2013 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the sales, revenue, market share and growth rate for the top players, key data from 2013 to 2018.

hosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.

Major factors driving the market include rise in prevalence of chronic diseases, high unmet medical needs, increase in the number of people undergoing dialysis, large geriatric population, and surge in public awareness worldwide. Diabetes and hypertension are the main causes of renal failure, which leads to hyperphosphatemia. However, stringent regulations by regulatory bodies such as the Food and Drug Administration (FDA), non-adherence to treatment regimens, and rise in side effects of hyperphosphatemia drugs are likely to inhibit the market. According to FDA use of hyperphosphatemia drugs for the treatment of high or low phosphorus levels in the human body is neither safe nor effective. High growth potential in untapped economies, such as India, China, South Africa, and Brazil, is expected to create lucrative opportunities for key players. Rise in geriatric population and increase in cases of osteoporosis in Asia Pacific is anticipated to drive the market. Osteoporosis is often undertreated and underdiagnosed, which is driving the hyperphosphatemia drugs market in Asia Pacific. The available calcium, lanthanum, sevelamer, and iron-based drugs for treating hyperphosphatemia are associated with certain side effects. The long-term use of calcium-based drugs such as calcium carbonate and calcium acetate can cause vascular calcification.

Request Sample Report Copy@ https://www.qyresearch.com/sample-form/form/835666/global-united-states-european-union-and-china-hyperphosphatemia-drugs-market

In this report, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Hyperphosphatemia Drugs.

In United States, European Union and China market, the following companies are covered:

Keryx Biopharmaceuticals

Sanofi

Shire

Vifor Pharma

Amgen

Bayer

...

Market Segment by Product Type

Aluminum Phosphate Binder

Iron Phosphate Binder

Magnesium Phosphate Binder

Calcium Phosphate Binder

Market Segment by Application

Hospitals

Clinics

Others

Key Regions split in this report:

United States

China

European Union

Rest of World (Japan, Korea, India and Southeast Asia)

Get Amazing Discount on Market Research Report@ https://www.qyresearch.com/request-discount/form/835666/global-united-states-european-union-and-china-hyperphosphatemia-drugs-market

About QYResearch
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.